M&A Deal Summary

Novo Nordisk Acquires Calibrium

On August 27, 2015, Novo Nordisk acquired life science company Calibrium

Acquisition Highlights
  • This is Novo Nordisk’s 2nd transaction in the Life Science sector.
  • This is Novo Nordisk’s 2nd transaction in the United States.
  • This is Novo Nordisk’s 2nd transaction in Indiana.

M&A Deal Summary
Date 2015-08-27
Target Calibrium
Sector Life Science
Buyer(s) Novo Nordisk
Deal Type Add-on Acquisition

Target

Calibrium

Indianapolis, Indiana, United States
Calibrium LLC is a biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novo Nordisk

Bagsvaerd, Denmark
Category Company
Founded 1923
Sector Life Science
Employees48,000
Revenue 232.3B DKK (2023)
DESCRIPTION
Novo Nordisk office in Zurich, Switzerland.
Novo Nordisk office in Zurich, Switzerland.

Novo Nordisk is a global pharmaceutical company dedicated to improving the lives of individuals affected by diabetes and other serious chronic conditions. Novo Nordisk develops and provides a comprehensive range of treatments, therapies, and medical solutions that help patients manage their health effectively. Novo Nordisk was formed in 1923 and is based in Bagsvaerd, Denmark.

DEAL STATS #
Overall 2 of 8
Sector (Life Science) 2 of 8
Type (Add-on Acquisition) 2 of 8
State (Indiana) 2 of 2
Country (United States) 2 of 5
Year (2015) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-27 MB2

Carmel, Indiana, United States

MB2 LLC is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class, mixed agonist drugs for the treatment of diabetes and obesity.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-08-17 Ziylo

Bristol, United Kingdom

Ziylo is a supramolecular chemistry company that has developed a third 'biomimetic' class of glucose binding molecules (GBMs). These molecules have potential to be a critical component in medical devices such as Continuous Glucose Monitors (CGM) and therapeutics such as Glucose Responsive Insulins (GRIs). Ziylo was founded in 2014 and is based in Bristol, United Kingdom.

Buy $800M
Mergr

Product

Company

Legal